Page last updated: 2024-10-23

aspirin and Gastroesophageal Reflux

aspirin has been researched along with Gastroesophageal Reflux in 50 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Gastroesophageal Reflux: Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER.

Research Excerpts

ExcerptRelevanceReference
"Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus."7.80Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014)
"Our data demonstrated that low dose aspirin reduced the incidence of duodenoesophageal reflux induced histological changes in the esophagus by preventing activation of proliferative & anti-apoptotic MAP kinases such as p38 & ER as well as protease activity."7.78Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways. ( Amirtharaj, GJ; Kettimuthu, K; Korula, A; Mathew, G; Nair, A; Nair, S; Ramachandran, A; Samuel, P; Selvan, B, 2012)
"There are several studies that suggest that aspirin (acetylsalicylic acid [ASA]) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with esophagitis or esophageal stricture formation."7.70NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? ( Davis, LP; Hunter, JG; Kim, SL; Waring, JP; Wo, JM, 1999)
" PPIs are the mainstay therapeutic agents for prophylaxis against aspirin gastropathy and for acid-related disorders including gastroesophageal reflux disease."4.95East Asian perspective on the interaction between proton pump inhibitors and clopidogrel. ( Goh, KL; Zou, D, 2017)
"Asthma has many triggers including rhinosinusitis; allergy; irritants; medications (aspirin in aspirin-exacerbated respiratory disease); and obesity."4.90Identifying asthma triggers. ( Ferguson, BJ; McCarty, JC, 2014)
"Aspirin has been proposed in recent years as a candidate for chemoprevention of adenocarcinoma in patients with Barrett's esophagus."3.80Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. ( Cebrián, C; Esquivias, P; García-González, MA; Lanas, A; Morandeira, A; Ortego, J; Piazuelo, E; Santander, S, 2014)
"Our data demonstrated that low dose aspirin reduced the incidence of duodenoesophageal reflux induced histological changes in the esophagus by preventing activation of proliferative & anti-apoptotic MAP kinases such as p38 & ER as well as protease activity."3.78Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways. ( Amirtharaj, GJ; Kettimuthu, K; Korula, A; Mathew, G; Nair, A; Nair, S; Ramachandran, A; Samuel, P; Selvan, B, 2012)
" Male gender, smoking, alcohol drinking, consumption of coffee, large waist circumference, infrequent medication of antacids, aspirin and NSAIDs, infrequent and mild GERD symptoms were all significantly associated with ED on univariate analysis."3.77[Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors]. ( Cho, KB; Jang, BI; Jeon, SW; Jung, JT; Jung, MK; Kim, ES; Kim, EY; Kim, KO; Kim, SK; Kwon, JG; Lee, JH; Lee, SH; Lee, SJ; Park, CK; Park, KS; Seo, HE; Yang, CH, 2011)
"There are several studies that suggest that aspirin (acetylsalicylic acid [ASA]) and nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with esophagitis or esophageal stricture formation."3.70NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus? ( Davis, LP; Hunter, JG; Kim, SL; Waring, JP; Wo, JM, 1999)
"Although low-dose acetylsalicylic acid (ASA) is recommended for prevention of cardiovascular events in at-risk patients, its long-term use can be associated with the risk of peptic ulcer and upper gastrointestinal (GI) symptoms that may impact treatment compliance."2.78Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial. ( Agewall, S; Herlitz, J; Lanas, A; Nagy, P; Nauclér, EC; Scheiman, JM; Svedberg, LE; Veldhuyzen van Zanten, SJ, 2013)
"15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily."2.77Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. ( Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012)
" Fifteen healthy Japanese volunteers are dosed for 7 days in a 5-way randomly crossover trial: placebo, aspirin 100 mg, rabeprazole 10 mg, and aspirin 100 mg plus rabeprazole 10 mg either once daily or 4 times per day."2.75Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Sugimura, H; Tanaka, T; Yamade, M, 2010)
"Abdominal obesity, independently of gastroesophageal reflux disease symptoms, is associated with increased risk of Barrett's esophagus and this association is likely mediated by high levels of leptin and insulin."2.53Determination of risk for Barrett's esophagus and esophageal adenocarcinoma. ( Thrift, AP, 2016)
"Barrett's metaplasia is one of the commonest premalignant lesions in the western world following colorectal adenomas."2.47Acid reflux and oesophageal cancer. ( Jankowski, J; Nicholson, A, 2011)
"In patients with Barrett's esophagus, medical treatment is necessary for the control of reflux symptom, healing of accompanying erosive esophagitis, and prevention of carcinogenesis."2.43[Medical treatment of Barrett's esophagus]. ( Kinoshita, Y; Yuki, T, 2005)
"Gastroesophageal reflux disease has a high incidence of 23%, with 29% of those with gastroesophageal reflux disease consuming nonsteroidal anti-inflammatory drugs."1.72In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin on Rabbit Esophageal Epithelium. ( Bor, S; Çağanoğlu, D; Ergün, P; Kıpçak, S, 2022)
" In study 2, 35 healthy subjects were treated with LDA 100 mg (regimen A), and then 20 randomly selected subjects were dosed clopidogrel 75 mg (regimen C), LDA/clopidogrel (regimen AC), or LDA/clopidogrel/rabeprazole 10 mg for 7 days."1.39Antiplatelet drugs are a risk factor for esophageal mucosal injury. ( Furuta, T; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2013)
"Risk factors associated with GERD were identified by logistic regression analysis in respondents who were not taking aspirin or proton pump inhibitors."1.35Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. ( Barthélémy, P; Ruszniewski, P; Soufflet, C, 2008)
" We assessed the presence of duration-response and dose-response effects."1.34Chronic proton pump inhibitor therapy and the risk of colorectal cancer. ( Hennessy, S; Hwang, WT; Lewis, JD; Propert, K; Sedarat, A; Yang, YX, 2007)

Research

Studies (50)

TimeframeStudies, this research(%)All Research%
pre-19906 (12.00)18.7374
1990's1 (2.00)18.2507
2000's17 (34.00)29.6817
2010's23 (46.00)24.3611
2020's3 (6.00)2.80

Authors

AuthorsStudies
Kıpçak, S1
Çağanoğlu, D1
Ergün, P1
Bor, S1
Kamal, H1
Sadr-Azodi, O1
Engstrand, L2
Brusselaers, N2
Hatakeyama, Y1
Horino, T1
Matsumoto, T1
Terada, Y1
Okuhara, Y1
Wahlin, K1
Lagergren, J1
Sugisaki, N1
Iwakiri, R1
Tsuruoka, N1
Sakata, Y1
Shimoda, R1
Fujimoto, S1
Eguchi, Y1
Fujimoto, K1
Sugimoto, M3
Uotani, T2
Nishino, M3
Yamade, M3
Sahara, S1
Yamada, T1
Osawa, S1
Sugimoto, K1
Umemura, K1
Watanabe, H1
Miyajima, H1
Furuta, T3
Steppuhn, H1
Langen, U1
Scheidt-Nave, C1
Keil, T1
Kim, SG1
Jung, HK1
Lee, HL1
Jang, JY1
Lee, H1
Kim, CG1
Shin, WG1
Shin, ES1
Lee, YC1
McCarty, JC1
Ferguson, BJ1
Cowie, A1
Noble, F1
Underwood, T1
Esquivias, P1
Cebrián, C1
Morandeira, A1
Santander, S1
Ortego, J1
García-González, MA1
Lanas, A2
Piazuelo, E1
Goldberg, A1
Gerkin, RD1
Young, M1
Thrift, AP2
Anderson, LA1
Murray, LJ1
Cook, MB1
Shaheen, NJ2
Rubenstein, JH1
El-Serag, HB1
Vaughan, TL1
Schneider, JL1
Whiteman, DC2
Corley, DA1
Zou, D1
Goh, KL2
Raschi, E1
Bianchin, M1
Poluzzi, E1
De Ponti, F1
Ruszniewski, P1
Soufflet, C1
Barthélémy, P1
Pandeya, N1
Webb, PM1
Sadeghi, S1
Green, AC1
Kodaira, C2
Ikuma, M2
Tanaka, T1
Sugimura, H1
Hishida, A1
Seite, F1
Delelis-Fanien, AS1
Valero, S1
Pradère, C1
Poupet, JY1
Ingrand, P1
Paccalin, M1
Triadafilopoulos, G1
Lombard, CM1
Jobe, BA1
Martín de Argila de Prados, C1
Scholl, S1
Dellon, ES1
Lee, SJ1
Jung, MK1
Kim, SK1
Jang, BI1
Lee, SH1
Kim, KO1
Kim, ES1
Cho, KB1
Park, KS1
Kim, EY1
Jung, JT1
Kwon, JG1
Lee, JH1
Yang, CH1
Park, CK1
Seo, HE1
Jeon, SW1
Nicholson, A1
Jankowski, J2
Selvan, B1
Ramachandran, A1
Korula, A1
Amirtharaj, GJ1
Kettimuthu, K1
Nair, S1
Nair, A1
Samuel, P1
Mathew, G1
Scheiman, JM1
Herlitz, J1
Veldhuyzen van Zanten, SJ1
Agewall, S1
Nauclér, EC1
Svedberg, LE1
Nagy, P1
Wepner, U1
Laheij, RJ2
Van Rossum, LG1
Jansen, JB2
Verheugt, FW2
Füessl, HS2
Singh, G1
Koop, H1
Bazzoli, F1
Kinoshita, Y1
Yuki, T1
Malfertheiner, P1
Fass, R1
Quigley, EM1
Modlin, IM1
Malagelada, JR1
Moss, SF1
Holtmann, G1
Katelaris, P1
Stanghellini, V1
Talley, NJ1
Tytgat, GN1
Wright, NA1
Leedham, S1
Ferrara, M1
Coppola, L1
Coppola, A1
Capozzi, L1
Slavin, RG1
Yang, YX1
Hennessy, S1
Propert, K1
Hwang, WT1
Sedarat, A1
Lewis, JD1
Kim, SL1
Hunter, JG1
Wo, JM1
Davis, LP1
Waring, JP1
Verbeek, AL1
Dyck, WP1
Smith, VM1
Siegel, SC1
Rachelefsky, GS1
Phillips, SF1
Ramirez-Mata, M1
Reyes, PA1
Alarcon-Segovia, D1
Garza, R1
Berman, PM1
Kirsner, JB1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Parallel-group, Multicentre, Phase III Study to Assess the Effect of Esomeprazole 20 or 40 mg od Versus Placebo on the Occurrence of Peptic Ulcers During 26 Weeks in Subjects on Continuous Low Dose Acetylsalicylic Acid (ASA)[NCT00441727]Phase 32,426 participants (Actual)Interventional2007-02-28Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Dyspepsia Dimension During the 26-week Visit or the Week Prior to the Last Visit.

RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequence ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). The dyspepsia dimension contains the items 'Burning feeling in the center of the upper stomach' and 'Pain in the center of the upper stomach'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.

Interventionparticipants (Number)
Esomeprazole 40 mg591
Esomeprazole 20 mg577
Placbo504

Number of Participants Reporting 0 in the Dichotomized RDQ (Reflux and Disease Questionnaire) Score (0 Versus >0) for the Gastroesophageal Reflux Disease Dimension During the 26-week Visit or the Week Prior to the Last Visit.

RDQ contains 12 items on a 6-point Likert scale. Six items concern the frequency ('Did not have' to 'Daily') and six items concern the severity ('Did not have' to 'Severe'). Gastroesophageal reflux disease (GERD) items: 'Acid taste in the mouth', 'Unpleasant movement of materials upward from the stomach', 'Burning feeling behind the breastbone' and 'Pain behind the breastbone'. Best score possible 0, worst score possible - daily occurrence. (NCT00441727)
Timeframe: RDQ was assessed at baseline, 8 weeks, 16 week, 26 weeks or upon withdrawal.

Interventionparticipants (Number)
Esomeprazole 40 mg554
Esomeproazole 20 mg537
Placebo451

Number of Participants With Gastric and/or Duodenal Erosions.

(NCT00441727)
Timeframe: The number of erosions was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal.

Interventionparticipants (Number)
Esomeprazole 40214
Esomeproazole 20213
Placebo380

Percentage of Participants Who Experienced the Occurence of Gastric Ulcer.

The occurrence of gastric ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks

Interventionpercentage of participants (Number)
Esomeprazole 401.1
Esomeproazole 200.75
Placebo4.1

Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).

The occurrence of ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks

Interventionpercentage of participants (Number)
Esomeprazole 401.35
Esomeproazole 201
Placebo6.58

Percentage of Participants Who Experienced the Occurrence of Duodenal Ulcer.

The occurrence of duodenal ulcer (mucosal break measuring >= 3 mm over its largest diameter with a sharply demarcated margin) was determined by endoscopy performed at baseline, 8 weeks and 26 weeks or upon withdrawal. (NCT00441727)
Timeframe: During 26 weeks

Interventionpercentage of participants (Number)
Esomeprazole 400.24
Esomeproazole 200.25
Placebo2.73

Reviews

13 reviews available for aspirin and Gastroesophageal Reflux

ArticleYear
Identifying asthma triggers.
    Otolaryngologic clinics of North America, 2014, Volume: 47, Issue:1

    Topics: Allergens; Aspirin; Asthma; Disease Progression; Female; Gastroesophageal Reflux; Humans; Male; Prog

2014
Strategies to improve outcomes in esophageal adenocarcinoma.
    Expert review of anticancer therapy, 2014, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; Barrett Esophagus; Combined Modality Therapy; Cytodi

2014
Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Current opinion in gastroenterology, 2016, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Disease Progres

2016
East Asian perspective on the interaction between proton pump inhibitors and clopidogrel.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:6

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anticoagulants; Asia, Eastern; Asian People; Aspirin; Clopi

2017
Acid reflux and oesophageal cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 185

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Cyclooxygenase 2; Esophageal Neoplasms; Esophagitis; Gas

2011
Understanding NSAID-PPI-COX-2 interrelationships.
    Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40 Suppl A

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Benzimida

2004
[Medical treatment of Barrett's esophagus].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:8

    Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Cycloo

2005
Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.
    Alimentary pharmacology & therapeutics, 2006, Mar-15, Volume: 23, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Gastrins; Gastroesoph

2006
Dilemmas in managing Barrett's oesophagus.
    Drug and therapeutics bulletin, 2006, Volume: 44, Issue:9

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Endoscopy, Gastrointestinal; Ga

2006
Iron deficiency in childhood and adolescence: retrospective review.
    Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3

    Topics: Adolescent; Anemia, Iron-Deficiency; Animals; Aspirin; Cattle; Celiac Disease; Child; Child, Prescho

2006
Medical management of rhinosinusitis comorbidities-asthma, aspirin sensitivity, gastroesophageal reflux, immune deficiencies.
    Clinical allergy and immunology, 2007, Volume: 20

    Topics: Aspirin; Asthma; Drug Hypersensitivity; Eosinophils; Gastroesophageal Reflux; Humans; Immunologic De

2007
Continuing medical education. Asthma in infants and children: Part 1.
    The Journal of allergy and clinical immunology, 1985, Volume: 76, Issue:1

    Topics: Airway Resistance; Allergens; Aspirin; Asthma; Asthma, Exercise-Induced; Bronchi; Child; Child, Pres

1985
Pathophysiology of gastritis: recent concepts and clinical significance.
    Southern medical journal, 1972, Volume: 65, Issue:10

    Topics: Aspirin; Bile; Ethanol; Gastric Mucosa; Gastritis; Gastroesophageal Reflux; Gastroscopy; Humans; Sto

1972

Trials

4 trials available for aspirin and Gastroesophageal Reflux

ArticleYear
Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.
    Journal of clinical pharmacology, 2010, Volume: 50, Issue:3

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Inflammatory Agents, Non-Steroid

2010
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
    Digestion, 2012, Volume: 85, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female;

2012
Esomeprazole for prevention and resolution of upper gastrointestinal symptoms in patients treated with low-dose acetylsalicylic acid for cardiovascular protection: the OBERON trial.
    Journal of cardiovascular pharmacology, 2013, Volume: 61, Issue:3

    Topics: Age Factors; Aged; Anti-Ulcer Agents; Aspirin; Cardiovascular Diseases; Dose-Response Relationship,

2013
Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial.
    Alimentary pharmacology & therapeutics, 2003, Jul-01, Volume: 18, Issue:1

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;

2003

Other Studies

33 other studies available for aspirin and Gastroesophageal Reflux

ArticleYear
In Vitro and In Vivo Effects of Nonsteroidal Anti-inflammatory Drugs and Aspirin on Rabbit Esophageal Epithelium.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2022, Volume: 33, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Epithelium; Gastroesophageal Reflux; Huma

2022
Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:4

    Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bile Duct Neoplasms; Bile

2021
Long-term continuous use of proton-pump inhibitors is associated with renal function decline in patients without acute kidney injury.
    Clinical and experimental nephrology, 2021, Volume: 25, Issue:10

    Topics: Acute Kidney Injury; Aged; Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal

2021
Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden.
    BMJ open, 2017, Oct-30, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Cohort Studies; Female; Gastro

2017
A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.
    Journal of gastroenterology, 2018, Volume: 53, Issue:12

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Case-Control Studies;

2018
Antiplatelet drugs are a risk factor for esophageal mucosal injury.
    Digestion, 2013, Volume: 87, Issue:4

    Topics: Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Aspirin; Case-Control Studies; Clopidogrel;

2013
Major comorbid conditions in asthma and association with asthma-related hospitalizations and emergency department admissions in adults: results from the German National Health Telephone Interview Survey (GEDA) 2010.
    BMC pulmonary medicine, 2013, Jul-12, Volume: 13

    Topics: Adolescent; Adult; Aged; Aspirin; Asthma; Comorbidity; Cross-Sectional Studies; Emergency Service, H

2013
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2013, Volume: 62, Issue:1

    Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal

2013
Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model.
    Oncology reports, 2014, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Animals; Aspirin; Barrett Esophagus; Dinoprostone; Disease Models, Animal; Esophagea

2014
Medical Prevention of Barrett's Esophagus: Effects of Statins, Aspirin, Non-aspirin NSAIDs, Calcium, and Multivitamins.
    Digestive diseases and sciences, 2015, Volume: 60, Issue:7

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Calcium; Case-Control Stu

2015
Nonsteroidal Anti-Inflammatory Drug Use is Not Associated With Reduced Risk of Barrett's Esophagus.
    The American journal of gastroenterology, 2016, Volume: 111, Issue:11

    Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Case-Cont

2016
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution.
    Neurogastroenterology and motility, 2017, Volume: 29, Issue:2

    Topics: Aspirin; Cardiovascular Diseases; Gastroesophageal Reflux; Humans; Proton Pump Inhibitors; Proton Pu

2017
Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study.
    Alimentary pharmacology & therapeutics, 2008, Nov-01, Volume: 28, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female

2008
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants?
    Gut, 2010, Volume: 59, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin;

2010
Compliance with guidelines for proton pump inhibitor prescriptions in a department of geriatrics.
    Journal of the American Geriatrics Society, 2009, Volume: 57, Issue:11

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Prescriptions; Femal

2009
"War and Peace" with Barrett's esophagus.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:4

    Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco

2011
[Security of proton pump inhibitors].
    Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:2

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child; Chronic Disease; Drug Interactions;

2011
Treatment of GERD and proton pump inhibitor use in the elderly: practical approaches and frequently asked questions.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:3

    Topics: Adenocarcinoma; Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Aspirin; Barrett Esop

2011
[Clinical characteristics of gastroesophageal reflux disease with esophageal injury in korean: focusing on risk factors].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, May-25, Volume: 57, Issue:5

    Topics: Adolescent; Adult; Aged; Alcohol Drinking; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Aspiri

2011
Low dose aspirin prevents duodenoesophageal reflux induced mucosal changes in wistar rat esophagus by MAP kinase mediated pathways.
    International journal of surgery (London, England), 2012, Volume: 10, Issue:2

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blotting, Western; Caspase 3;

2012
[A case for proton pump blocker... When cough comes from the stomach].
    MMW Fortschritte der Medizin, 2002, Nov-07, Volume: 144, Issue:45

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Age

2002
[Heartburn without esophagitis. Symptoms more important than the finding?].
    MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39

    Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul

2003
[Helicobacter pylori: changes of indications for eradication therapy].
    Deutsche medizinische Wochenschrift (1946), 2004, Sep-03, Volume: 129 Suppl 2

    Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Aspirin; Drug Therapy, Combination; Gastroesophageal Reflu

2004
Definitions and classification of dyspepsia: pH, Helicobacter pylori, non-steroidal anti-inflammatory drugs--should we include gastro-oesophageal reflux disease?
    Alimentary pharmacology & therapeutics, 2005, Volume: 21 Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dyspepsia; Gastroesophageal Reflux; Helicobacter I

2005
The evidence base of proton pump inhibitor chemopreventative agents in Barrett's esophagus--the good, the bad, and the flawed!
    The American journal of gastroenterology, 2007, Volume: 102, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Barrett Esophagus; Chemoprevent

2007
Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
    Gastroenterology, 2007, Volume: 133, Issue:3

    Topics: Adenocarcinoma; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studies; Colore

2007
[Family practice highlights of stomach, liver and intestinal reference points. Your arsenal against abdominal problems].
    MMW Fortschritte der Medizin, 2007, Nov-29, Volume: 149, Issue:48

    Topics: Alcohol Drinking; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Barrett Esophagus; Family Practi

2007
NSAIDs, aspirin, and esophageal strictures: are over-the-counter medications harmful to the esophagus?
    Journal of clinical gastroenterology, 1999, Volume: 29, Issue:1

    Topics: Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Endoscopy, Gastrointestinal; Esophage

1999
Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease.
    Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:7

    Topics: Aspirin; Calcium Channel Blockers; Deglutition Disorders; Dyspepsia; Fibrinolytic Agents; Flatulence

2001
Pathophysiologic considerations in peptic ulcer disease.
    Southern medical journal, 1979, Volume: 72, Issue:3

    Topics: ABO Blood-Group System; Adrenal Cortex Hormones; Aspirin; Bicarbonates; Environment; Female; Gastric

1979
Association of aspirin ingestion with symptomatic esophageal hiatus hernia.
    Southern medical journal, 1978, Volume: 71 Suppl 1

    Topics: Aspirin; Barium Sulfate; Esophagitis, Peptic; Esophagogastric Junction; Esophagus; Gastroesophageal

1978
Esophageal motility in systemic lupus erythematosus.
    The American journal of digestive diseases, 1974, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Aged; Aspirin; Azathioprine; Chloroquine; Deglutition Disorders; Dilatation; Drug

1974
Recognizing and avoiding adverse gastrointestinal effects of drugs.
    Geriatrics, 1974, Volume: 29, Issue:6

    Topics: Aged; Antacids; Aspirin; Colon; Digestive System; Drug Antagonism; Drug Interactions; Drug-Related S

1974